- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about AZN
Recent news which mentions AZN
AstraZeneca Blames 'Toxic' Climate As It Walks Away from Over $550 Million UK Vaccine Plant
February 03, 2025
From Benzinga
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
January 29, 2025
From Benzinga
FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients
January 28, 2025
From Benzinga
From Benzinga
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
January 22, 2025
From Benzinga
From Benzinga
From Benzinga
3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever
January 21, 2025
From Motley Fool
AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline
January 17, 2025
From Benzinga
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
January 17, 2025
From Benzinga
FDA Approves AstraZeneca's Calquence Combo Therapy For Untreated Mantle Cell Lymphoma
January 17, 2025
From Benzinga
From Motley Fool
3 Cheap Growth Stocks to Buy in 2025
January 09, 2025
From Motley Fool
Better Buy: Novo Nordisk vs. AstraZeneca
January 04, 2025
From Motley Fool
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
January 02, 2025
From Benzinga
Why IonQ Is the Best Quantum Computing Stock to Buy Right Now
December 26, 2024
From Motley Fool
Achilles Therapeutics Announces $12M AstraZeneca Deal, Plans Job Cuts
December 24, 2024
From Benzinga
FDA Rejects Johnson & Johnson's Injectable Version Of Approved Drug For Lung Cancer
December 17, 2024
From Benzinga
3 Unstoppable Stocks to Buy Right Now
December 15, 2024
From Motley Fool
From Benzinga
United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis
December 13, 2024
From Benzinga
AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients
December 11, 2024
From Benzinga
2 No-Brainer Dividend Stocks With Yields Over 3% to Buy in 2025 and Hold for a Decade or Longer
December 09, 2024
From Motley Fool
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
December 06, 2024
From Benzinga
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer
December 06, 2024
From Benzinga
FDA Approves AstraZeneca's Blockbuster Cancer Drug Imfinzi For Aggressive Form Of Lung Cancer
December 05, 2024
From Benzinga
Jim Cramer Prefers FedEx Over This Delivery Giant That 'Screwed Up A Lot Of Holiday Seasons'
December 03, 2024
From Benzinga
From Benzinga
3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now
November 21, 2024
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.